77,451 Shares in Omada Health, Inc. $OMDA Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH purchased 77,451 shares of Omada (~$1.22M) in Q4, representing about 0.13% of the company, while several other institutions also initiated small stakes.
• Analysts hold a consensus "Moderate Buy" rating with a $21.64 average target, amid mixed research moves (Citigroup initiated "outperform", JPMorgan cut its target to $26, Barclays cut to $17, and Wall Street Zen upgraded to "buy").
• Omada trades near $15.29 with a ~$909M market cap; it posted an EPS beat last quarter ($0.08 vs. -$0.04) on $75.85M revenue, and insiders have executed modest sales recently.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Omada Health, Inc. (NASDAQ:OMDA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 77,451 shares of the company's stock, valued at approximately $1,222,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.13% of Omada Health as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of OMDA. TD Waterhouse Canada Inc. bought a new stake in Omada Health during the 4th quarter worth approximately $32,000. Raymond James Financial Inc. bought a new position in shares of Omada Health during the 2nd quarter worth approximately $32,000. Strs Ohio bought a new position in shares of Omada Health during the 3rd quarter worth approximately $38,000. Inlight Wealth Management LLC bought a new position in shares of Omada Health during the 4th quarter worth approximately $45,000. Finally, Rakuten Investment Management Inc. bought a new position in shares of Omada Health during the 3rd quarter worth approximately $49,000.

Analysts Set New Price Targets

OMDA has been the subject of several research reports. Citigroup initiated coverage on shares of Omada Health in a research note on Tuesday, April 14th. They set an "outperform" rating for the company. JPMorgan Chase & Co. decreased their price target on shares of Omada Health from $32.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, March 12th. Wells Fargo & Company initiated coverage on shares of Omada Health in a research note on Thursday, January 8th. They set an "equal weight" rating and a $17.00 price target for the company. Barclays decreased their price target on shares of Omada Health from $22.00 to $17.00 and set an "overweight" rating for the company in a research note on Tuesday, March 3rd. Finally, Wall Street Zen raised shares of Omada Health from a "hold" rating to a "buy" rating in a research note on Saturday, March 14th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Omada Health currently has an average rating of "Moderate Buy" and a consensus target price of $21.64.

Omada Health Trading Up 4.9%

NASDAQ OMDA opened at $15.29 on Friday. The company has a market cap of $908.53 million and a PE ratio of -89.94. Omada Health, Inc. has a 12 month low of $10.28 and a 12 month high of $28.40. The stock has a 50 day moving average of $13.28 and a 200-day moving average of $16.10.

Omada Health (NASDAQ:OMDA - Get Free Report) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.12. The company had revenue of $75.85 million during the quarter. As a group, sell-side analysts predict that Omada Health, Inc. will post -0.04 EPS for the current fiscal year.

Insider Activity

In other news, President Wei-Li Shao sold 2,829 shares of the stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $12.71, for a total value of $35,956.59. Following the completion of the sale, the president owned 328,850 shares of the company's stock, valued at approximately $4,179,683.50. This represents a 0.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Steven L. Cook sold 1,884 shares of the stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $13.94, for a total value of $26,262.96. Following the completion of the sale, the chief financial officer directly owned 200,512 shares of the company's stock, valued at approximately $2,795,137.28. The trade was a 0.93% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 8,776 shares of company stock valued at $120,483.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

Want to see what other hedge funds are holding OMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omada Health, Inc. (NASDAQ:OMDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.